GlassScriptPhysician profile
Trenton Drew Custis
NPI 1356575344
$3,856.88
in general payments reported to CMS, 2019-2025
30 companies · $1,487 in 2025
The $1,487 reported for 2025 was more than what 83% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $240 · 2021: $205 · 2022: $584 · 2023: $289 · 2024: $639 · 2025: $1,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,399 · Education: $15.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,399.16 |
| Education | $15.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $581.85 | 2019-2024 | |
| Amgen INC. | $358.50 | 2022-2025 | Otezla |
| Ucb, INC. | $320.67 | 2019-2025 | Bimzelx |
| Kerecis Limited | $299.84 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Genzyme Corporation | $299.20 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $292.71 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $266.91 | 2022-2025 | Tremfya |
| Abbvie INC. | $209.35 | 2021-2025 | Botox |
| Lilly USA, LLC | $206.90 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $145.36 | 2019-2025 | Adbry, Anzupgo |
| Incyte Corporation | $119.48 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $109.10 | 2019-2020 | |
| Almirall LLC | $103.64 | 2022-2025 | Klisyri, Seysara |
| Mayne Pharma Commercial LLC | $91.26 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $74.89 | 2023-2025 | Ilumya |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $47.71 | 2019 | |
| Journey Medical Corporation | $41.09 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $38.66 | 2019-2023 | Siliq |
| Nabriva Therapeutics, Plc | $34.27 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $27.67 | 2022 | |
| Cipher Pharmaceuticals US LLC | $27.25 | 2025 | Natroba, Spinosad |
| Convatec INC. | $26.21 | 2025 | |
| Janssen Scientific Affairs, LLC | $20.31 | 2019 | |
| Organon LLC | $19.07 | 2025 | Hadlima |
| Encore Dermatology INC. | $18.94 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.76 | 2020 | |
| Genentech USA, INC. | $15.81 | 2022 | |
| Celgene Corporation | $15.56 | 2019 | |
| Smith+Nephew, INC. | $14.94 | 2024 | Grafix Pl |
| Merck Sharp & Dohme LLC | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trenton Custis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.